Arch Therapeutics Inc
OTC:ARTH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Arch Therapeutics Inc
Net Income (Common)
Arch Therapeutics Inc
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Arch Therapeutics Inc
OTC:ARTH
|
Net Income (Common)
-$13m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-3%
|
|
|
Haemonetics Corp
NYSE:HAE
|
Net Income (Common)
$175.4m
|
CAGR 3-Years
22%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
ICU Medical Inc
NASDAQ:ICUI
|
Net Income (Common)
$732k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-62%
|
CAGR 10-Years
-34%
|
|
|
Align Technology Inc
NASDAQ:ALGN
|
Net Income (Common)
$410.4m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
11%
|
|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Net Income (Common)
$233.6m
|
CAGR 3-Years
103%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
Net Income (Common)
$128.5m
|
CAGR 3-Years
20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
18%
|
|
Arch Therapeutics Inc
Glance View
Arch Therapeutics, Inc. is a development stage biotechnology company, which engages in the development and provision of hemostasis and sealant technology platform. The company is headquartered in Framingham, Massachusetts and currently employs 10 full-time employees. The company went IPO on 2012-06-27. The firm's technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids. The Company’s flagship products and product candidates are derived from its AC5 self-assembling peptide (SAP) technology platform and also referred to as AC5 or the AC5 Devices. These include AC5 Advanced Wound System and AC5 Topical Hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. Other products are in development for use in minimally invasive or open surgical procedures and include AC5-GTM for gastrointestinal endoscopic procedures and AC5-V and AC5 Surgical Hemostat for hemostasis inside the body.
See Also
What is Arch Therapeutics Inc's Net Income (Common)?
Net Income (Common)
-13m
USD
Based on the financial report for Jun 30, 2024, Arch Therapeutics Inc's Net Income (Common) amounts to -13m USD.
What is Arch Therapeutics Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-3%
Over the last year, the Net Income (Common) growth was -103%. The average annual Net Income (Common) growth rates for Arch Therapeutics Inc have been -30% over the past three years , -20% over the past five years , and -3% over the past ten years .
